Innovent doses first patient in bispecific antibody clinical trial
Category: #health  By Pankaj Singh  Date: 2019-04-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Innovent doses first patient in bispecific antibody clinical trial

Innovent Biologics, Inc., a top-notch biopharmaceutical firm which produces and commercializes superior quality medications, has recently declared that the first patient has successfully been dosed in China in the Phase 1 trial of a recombinant completely human bispecific antibody aiming programmed cell death receptor-1 & programmed cell death ligand-1, a revolutionary antibody developed in partnership with Eli Lilly & Company.

The Phase I clinical research CIBI318A101 is being performed in China to assess IBI318 for curing patients suffering with advanced malignancies. The main objective of the research is to evaluate the tolerability, safety, and preliminary efficacy of IBI318, cited authentic sources.

For the uninitiated, IBI318 is recombinant completely human IgG1 bispecific antibody aiming PD-1 & PD-L1, having the potential to offer a new solution to patients’ unfulfilled medicinal needs. IBI318 binds to PD-L1 and PD-1 at the same time, blocks PD-L1 and PD-1 signals, connects PD-L1-expressing tumor cells and PD-1-expressing T cells, while enhancing immune synapses formation, hence potentially augmenting anti-tumor actions and amplified anti-tumor efficacy.

According to Professor Xu Ruihua, Sun Yat-Sen University Cancer Center’s Director, immunotherapies like checkpoint blocking antibodies aiming PD-L1 and PD-1 have a significant role in oncology treatment. However, their clinical applications are still prone to several challenges, mainly, for patients lacking predictive biomarkers, the experimental response rate is roughly 20 percent, Ruihua stated, adding that several patients also have acquired or primary resistance to anti-PD-L1/PD-1 antibodies,.

Xu Ruihua further mentioned that the immunotherapy’s next generation still needs to be actively built and the university looks forward to viewing the IBI318 clinical results, Xu Ruihua added.  

Michael Yu, CEO, Chairman and Founder of Innovent, was quoted stating that IBI318 is the first PD-L1/PD-1 bispecific antibody to start clinical development. Hence, the formulation of IBI318 has exclusive clinical value. Yu also said that the firm would assess the possible clinical value of this medicinal candidate and hopes to offer a highly effective therapeutic option and finally help more patients.

Source credit

http://innoventbio.com/en/#/news/140

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Merck acquires Calporta Therapeutics from COI Pharmaceuticals
Merck acquires Calporta Therapeutics from COI Pharmaceuticals
By Pankaj Singh

Merck will pay up to $576 million for the acquisition   Preclinical TRPML1 has the potential to treat neurodegenerative and lysosomal disorders COI Pharmaceuticals has recently announced that Merck, also called MSD outside Canada and the U...

Personalis unveils new service for cancer whole genome sequencing
Personalis unveils new service for cancer whole genome sequencing
By Pankaj Singh

  The new launch of the services will help the company expand its oncology portfolio Personalis has been able to sequence more than 40,000 MVP samples since 2013. Personalis, Inc., a leading advanced genomics firm for cancer, recently unve...

Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
Celltrion depicts CT-P13 SC efficacy for treating rheumatoid arthritis
By Pankaj Singh

Celltrion Healthcare, a biopharmaceutical company, recently announced data from a study further investigating efficacy, safety, immunogenicity & pharmacokinetics of CT-P13 SC, over a period of 1-year treatment. The study focuses on the results ac...